

16 June 2025 Sydney, Australia

Non-Deal Investor Presentation

Nyrada Inc (ASX:NYR), a clinical stage drug discovery and development company focused on innovative Transient Receptor Potential Canonical (TRPC) ion channel inhibitors provides the enclosed investor presentation in connection with a non-deal investor roadshow commencing on Monday 16 June 2025.

-ENDS-

About Nyrada Inc.

Nyrada Inc. is a clinical stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, Xolatryp™, has shown efficacy in both neuroprotection and cardioprotection, positioning it for a first-in-human Phase I clinical trial. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, USA, with limited liability for its stockholders.

www.nyrada.com

Authorised by Mr. John Moore, Non-Executive Chair on behalf of the Board.

Investors and Media:
Dimitri Burshtein
T: 02 9498 3390
E: info@nyrada.com

Company Secretary:
David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.

Investor Presentation

June 2025

Improving Lives, Offering Hope

ASX:NYR

Authorised by Mr. John Moore, Non-Executive Chair, on behalf of the Board.

Important Notice and Disclaimer

This presentation has been prepared by Nyrada Inc **("NYR"** or **"Company"**). It should not be considered as an offer or invitation to subscribe for, or purchase any securities in NYR, or as an inducement to purchase any securities in NYR. No agreement to subscribe for securities in NYR will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. In particular, this presentation may not be released to US wire services or distributed in the United States.

This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or to, or for the account or benefit of, US persons. The Company's CDIs have not been, and will not be, registered under the US Securities Act or the securities laws of any state or other jurisdiction of the United States. The CDIs may not be offered, sold or otherwise transferred in the United States except in a transaction exempt from, or not subject to, the registration requirements of the US Securities Act of 1933 and the applicable securities laws of any state or other jurisdiction in the United States. No person in the United States may, directly or indirectly, participate in the Company's Security Purchase Plan.

It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice, and the Company is not licensed to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place.

Such forward-looking statements do not guarantee of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making.

Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

About Nyrada

- Clinical stage drug discovery and development company focused on innovative small molecule Transient Receptor Potential Canonical (TRPC) ion channel inhibition.
- Lead drug candidate Xolatryp™ (previously known as NYR-BI03) currently in Phase I safety and tolerability clinical trial
- Low-cost exploration for other indications.
- Lean operating model leveraging best in class third party service and research providers.
- Commercially focused business model, expert team, and impressive board with a track record of success.

About Xolatryp™

- Third generation, small molecule TRPC ion channel inhibitor developed using rational drug design.
- Previously known as NYR-BI03.
- Sound scientific foundation with underlying target proven in genetically modified mouse knock-out model.
- Blocks TRPC 3, 6 and 7 channels.
- Novel and well understood mechanism of action.
- Passes blood-brain barrier necessary for treatment of secondary brain injury, including following stroke and TBI.
- Protected by composition of matter patent application.

One Drug

Xolatryp™

Two Applications

Neuroprotection

Cardioprotection

Three Markets

STROKE

~US$52.2 billion by 2030[2]

TRAUMATIC BRAIN INJURY

~US$5.5 billion by 2030[4]

MYOCARDIAL INFARCTION

~US$3.7 billion by 2032[5]

About TRPC Channel Inhibition

- **Activation** following injury **results in calcium entry** via TRPC ion channels
- **Excessive calcium** build-up leads to **cell death**
- **Inhibiting TRPC 3/6/7 ion channels is neuro- and cardio- protective**



Organ	Cell Type	TRPC Activation Effect	Xolatryp Inhibition Effect
Brain	**Neurons**	Calcium overload → neuron death	Reduces neuron loss, protects function
	Astrocytes	Impaired regulation → inflammation	Restores balance, reduces swelling
	Microglia	Excessive inflammation	Limits harmful immune response
Heart	**Cardiomyocytes**	Calcium overload → cell death, scarring	Prevents damage, improves contraction
	Endothelial	Impaired repair → poor blood flow	Enhances vessel repair, reduces inflammation
	Fibroblasts	Excessive scarring → stiff heart	Limits scarring, preserves flexibility

Phase I Clinical Trial

Key Study Features

- ✓ Primary Endpoints:
  - ✓ safety and tolerability of Xolatryp healthy volunteers, when administered as an intravenous infusion for up to 6 hours
- ✓ Secondary Endpoints:
  - ✓ blood pharmacokinetics of an intravenous dose of Xolatryp in healthy volunteers when administered as an intravenous infusion for up to 6 hours
- ✓ Double-blind, placebo-controlled, randomised.
- ✓ Up to approximately 48 participants (8 participants per cohort for 6 cohorts)

Status

- ✓ Cohort 4 (of 6) results reported.
- ✓ Cohort 5 to commence.
- ✓ Final trial results expected in quarter ending September 2025

Ischemic Stroke

- Statistically significant neuroprotection from secondary brain injury
- MRI analysis undertaken by UNSW Sydney using a specialised technique known as fractional anisotropy (FA) to visualise structural damage in the penumbra.
- **42%** neuroprotection was seen in the penumbra region of Xolatryp treated animals compared with vehicle treated animals.
- **41%** decrease in NfL levels



Traumatic Brain Injury (TBI)

- Joint study with US Department of Defence (Walter Reed Army Institute of Research) and UNSW Sydney
- Statistically significant neuroprotection



Myocardial Infarction (1)

Key Preclinical Results:





Xolatryp showed strong efficacy limiting cardiovascular damage resulting from myocardial ischemia-reperfusion (IR) injury

- **86%** Cardioprotection
- **43%** increase in left ventricular ejection fraction
- **50%** increase in fractional shortening

Key blood biomarker markers assessed

- **42%** decrease in AST levels
- **45%** decrease in LDH levels
- **32%** decrease in Troponin I

Superior efficacy compared to FDA-approved, Captopril



Myocardial Infarction (2)

Key Preclinical Results:

Xolatryp showed strong efficacy limiting cardiovascular damage resulting from myocardial ischemia-reperfusion injury when administered as a short-duration intravenous infusion

- **42%** Cardioprotection
- **88%** decrease in arrhythmias at 1 hour
- **90%** decrease in arrhythmias at 3 hours

Key blood biomarker markers assessed
- **32%** decrease in Troponin I
- **21%** decrease in in ALT levels





Conclusion

- **Summary**
  - Pioneering TRPC channel inhibition therapies.
  - Xolatryp Phase I (safety and tolerability) clinical trial well advanced
  - Xolatryp preclinical efficacy demonstrated in ischemic stroke, traumatic brain injury (TBI) and myocardial ischemia reperfusion injury
  - AU$4.76 million cash position at end March 2025

- **News Flow/Catalysts**
  - 4QFY2025 Cashflow update – June 2025
  - FY2025 Audited accounts – August 2025
  - Final Phase I Clinical Trial Results – September 2025
  - Phase II Clinical Trial Target and Plan – TBA

Key Market Announcements

- Phase I Clinical Trial
  - Protocol Amendment – June 2024
  - Cohort 3 Update – May 2024
- Ischemic Stroke
  - Preclinical Study – February 2024
- Traumatic Brain Injury (TB()
  - Preclinical Study – April 2025
- Acute Myocardia Ischemia
  - Preclinical Study – October 2024
  - Supplementary Preclinical Study – October 2024
  - Follow up Preclinical Study – May 2025



Appendices

Vision and Strategy

Our Vision:

- to become a high-growth pharmaceutical company specialising in the discovery and development of novel treatments

Our Strategy:

- to develop treatments for diseases where there is an unmet clinical need, or where current treatments are suboptimal, and to monetise the value of these treatments through advancing clinical drug candidates towards out-licencing.

Large Market Opportunity – Myocardial Infarction

Globally:

~15-20 million people suffer heart attack annually

~15% mortality within 30 days

No current FDA approved treatments targeting myocardial infarction-reperfusion injury

Effective treatment will improve patient outcomes and reduce high costs associated with long-term care of heart attack survivors.

Large and growing treatment market:

Currently **~US$1.9 billion[5]**

Growing **~6.8% CAGR[5]**

Forecast **~US$3.7 billion by 2032[5]**



Large Market Opportunity – Stroke

Globally:

~15 million people suffer strokes annually[1]

~5 million left permanently disabled[1]

One approved drug class for stroke suitable for <15% of patients (tPA - tissue plasminogen activator).

Effective treatment will improve patient outcomes and reduce high costs associated with long-term care.

Large and growing treatment market:

Currently **~US$30.3 billion[2]**

Growing **~7.5% CAGR[2]**

Forecast **~US$52.2 billion by 2030[2]**

Large Market Opportunity – Traumatic Brain Injury (TBI)

Globally:

~5.5 million people suffer severe TBA annually[3]

~55 million living with effects of medically treated TBI[3]

No current FDA approved treatments

Effective treatment will improve patient outcomes and reduce high costs associated with long-term care of brain injury survivors.

Large and growing treatment market:

Currently **~US$3.5 billion[4]**

Growing **~6.2% CAGR[4]**

Forecast **~US$5.5 billion by 2030[4]**



Neuroprotection – Stroke and TBI

Serial reconstruction from MRI





Nyrada drug Xolatryp
An acute 3-day intravenous treatment

Reduce secondary injury resulting from stroke or TBI

- Improve survivability, limit disability
- Improve quality of life

Drug Development Cycle

Discovery & Development

Scientists study how a disease affects patients and look for potential compounds that might help treat these diseases

Preclinical research

Once promising compounds are found, scientists begin to test the compounds in the lab and on animals

Clinical trials

If the compounds pass preclinical tests, it is then tested on humans to confirm effectiveness, safety, and optimal dosage.

FDA review

After clinical trials, the company sends all data to the FDA so that they can review the drug's safety and effectiveness.

Post-market safety monitoring

After a drug is approved by the FDA, scientists continue to monitor both the drug's safety and effectiveness.

Potential for Xolatryp out-licencing

References

1 – World Health Organization - https://www.emro.who.int/health-topics/stroke-cerebrovascular-accident/index.html#:~:text=Annually%2C%2015%20million%20people%20worldwide,cause%20is%20high%20blood%20pressure

2 – Databridge Market Research - https://www.databridgemarketresearch.com/reports/global-stroke-market .

3 – National Academy of Sciences - https://nap.nationalacademies.org/catalog/25394/traumatic-brain-injury-a-roadmap-for-accelerating-progress

4 – Databridge Market Research - https://www.databridgemarketresearch.com/reports/global-traumatic-brain-injuries-treatment-market

5 – Spherical Insights – https://www.globenewswire.com/en/news-release/2023/05/30/2678779/0/en/Global-Myocardial-Infarction-Market-Size-To-Grow-USD-3-7-Billion-By-2032-CAGR-of-6-8.html



@nyrada_inc

@nyrada_inc

info@nyrada.com

www.nyrada.com